Literature DB >> 15215145

rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin.

Wafa Achour1, Olfa Guenni, Marguerite Fines, Roland Leclercq, Assia Ben Hassen.   

Abstract

Activity of rifampin against 129 Streptococcus mitis isolates obtained from patients with hematologic cancer was investigated. One hundred twenty-five strains were susceptible to rifampin, and 4 were resistant (MIC = 32 to 64 microg/ml). Resistance to rifampin was related to mutations in the rpoB gene: His(526)Asn in three strains and His(526)Asp in one strain.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15215145      PMCID： PMC434179          DOI： 10.1128/AAC.48.7.2757-2759.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.

Authors:  T A Wichelhaus; V Schäfer; V Brade; B Böddinghaus
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  rpoB mutation conferring rifampin resistance in Streptococcus pyogenes.

Authors:  Hélène Aubry-Damon; Marc Galimand; Guy Gerbaud; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Rifampin resistance in Streptococcus pyogenes.

Authors:  L Herrera; C Salcedo; B Orden; B Herranz; R Martinez; A Efstratiou; J A Sáez Nieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-05-17       Impact factor: 3.267

4.  Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains.

Authors:  P Stefanelli; C Fazio; G La Rosa; C Marianelli; M Muscillo; P Mastrantonio
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

5.  Molecular basis of rifampin resistance in Streptococcus pneumoniae.

Authors:  T Padayachee; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Characterization of mutations in the rpoB gene associated with rifampin resistance in Rhodococcus equi isolated from foals.

Authors:  M Fines; S Pronost; K Maillard; S Taouji; R Leclercq
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

7.  Molecular analysis of rifampin resistance in Bacillus anthracis and Bacillus cereus.

Authors:  Amy J Vogler; Joseph D Busch; Stephanie Percy-Fine; Christine Tipton-Hunton; Kimothy L Smith; Paul Keim
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Viridans group streptococci: a reservoir of resistant bacteria in oral cavities.

Authors:  A Bryskier
Journal:  Clin Microbiol Infect       Date:  2002-02       Impact factor: 8.067

9.  Low-level resistance to rifampin in Streptococcus pneumoniae.

Authors:  Patricia Stutzmann Meier; Silvia Utz; Suzanne Aebi; Kathrin Mühlemann
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

10.  Emergence of rifampin-resistant Rhodococcus equi with several types of mutations in the rpoB gene among AIDS patients in northern Thailand.

Authors:  Norichika Asoh; Hiroshi Watanabe; Marguerite Fines-Guyon; Kiwao Watanabe; Kazunori Oishi; Weerayut Kositsakulchai; Tippaya Sanchai; Khemrassamee Kunsuikmengrai; Sumpun Kahintapong; Banyong Khantawa; Prasit Tharavichitkul; Thira Sirisanthana; Tsuyoshi Nagatake
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948
View more
  2 in total

1.  New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae.

Authors:  María-José Ferrándiz; Carmen Ardanuy; Josefina Liñares; Luz Balsalobre; María Teresa García; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

2.  Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes.

Authors:  Steve Mullin; David M Rothstein; Christopher K Murphy
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.